Related Experiment Video

Updated: May 11, 2026

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

A novel protein C inhibitor gene mutation in pediatric stroke patients after bone marrow transplantation

Didem Torun1, Gülhis Deda, Mehmet Ertem

  • 1Biotechnology Institute, Ankara University, Ankara, Turkey. didemtorun@gmail.com

Molecular Biology Reports
|May 15, 2013
PubMed

Insights

Researchers identified a specific gene mutation in Turkish pediatric stroke patients, linking Protein C inhibitor gene alterations to stroke in children. This finding may improve understanding of pediatric stroke causes.

Area of Science:

  • Genetics
  • Hematology
  • Pediatric Neurology

Background:

  • Protein C inhibitor is a crucial plasma protein regulating coagulation.
  • Pediatric stroke represents a significant health concern with complex etiologies.
  • Genetic factors are increasingly recognized in the pathogenesis of childhood stroke.

Purpose of the Study:

  • To investigate the role of Protein C inhibitor gene mutations in Turkish pediatric stroke patients.
  • To identify specific genetic alterations associated with stroke in this cohort.

Main Methods:

  • Analysis of the Protein C inhibitor gene in pediatric stroke cases.
  • Genetic sequencing to detect mutations, specifically in exon 2.

Main Results:

  • A missense mutation (G to A at nucleotide 6760, p.Ser188Asp) in exon 2 of the Protein C inhibitor gene was identified.
  • This mutation was found in a pediatric stroke patient, his father, and another pediatric stroke case post-bone marrow transplantation.

Conclusions:

  • The identified Protein C inhibitor gene mutation may be associated with pediatric stroke.
  • Further research is warranted to elucidate the functional impact and prevalence of this mutation in pediatric stroke.

More Related Videos

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer09:39

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer

Published on: June 9, 2018

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...